Earlier detection of prostate cancer
An improved test for prostate cancer promises to improve the detection and monitoring of the most common form of cancer affecting men in the...
More patients to benefit from Xeloda
Roche’s Xeloda (capecitabine) has been approved by the European Commission for post-surgery treatment of patients with early colon cancer. The drug is indicated in...
Pharma employees more loyal than ever
A quarter of employees in the pharmaceutical sector are more loyal to their employer as a direct result of the economic downturn, according to...
Boehringer fosters innovation in life sciences
Boehringer Ingelheim has launched a new fund to invest in companies that provide ground-breaking therapeutic approaches and technologies to help drive innovation in medical...
NHS plan to develop commercial skills
The new NHS Commercial Support Units will help local and regional decision-makers to support the quality and productivity agenda by building effective relationships with...
NICE reveals first ever fellows and scholars
Lord Ara Darzi, Chair of Surgery at Imperial College London and former Health Minister, has been appointed as NICE’s first honorary Fellow. A further...
EC approves combination ACS treatment
The European Commission has approved Sanofi-aventis and Bristol-Myers Squibb’s dual antiplatelet combination tablet DuoPlavin/DuoCover (clopidogrel and acetylsalicylic acid). The combination treatment is indicated for...
CHMP Update March
The March meeting of the CHMP saw no new branded drugs recommended for approval, though several generics secured positive opinions. The Committee adopted a...
Movetis launches Resolor in the UK
Movetis’ Resolor (prucalopride) is now available in the UK to treat the symptoms of chronic constipation in women who do not receive adequate relief...
Norgine opens R&D centre in Wales
European speciality pharmaceutical company Norgine is to open a new £4 million Technology Development Centre in Hengoed, South Wales. The new facility is a...
Latest articles
NICE recommendation for GSK’s ovarian cancer treatment
National Institute for Health and Care Excellence (NICE) has recommended GSK’s ZEJULA®▼ (niraparib) on the NHS in England for women with advanced high-grade epithelial...
Victims of abuse given code word to ask pharmacists for help
Victims of domestic abuse will be able to access much needed support from thousands of pharmacies across the UK, in a new scheme backed...
Positive trial results for Eli Lilly’s Donanemab in Alzheimer’s
A positive Phase 2 Trial of Eli Lilly’s donanemab, an investigational antibody, has shown significant slowing of decline in a composite measure of cognition...
Popular articles
Study shows anti-parasitic drug ivermectin kills coronavirus within 48 hours
A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint...
Nasal spray to protect against COVID-19 is ready for use in humans
A nasal spray to provide protection against the COVID-19 virus has been formulated by researchers at the University of Birmingham, UK, using compounds already...
New Normal, New Thinking: Life Post COVID-19
New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
JCVI updates priority list for COVID-19 vaccine
The Joint Committee on Vaccination and Immunisation (JCVI) has advised that the first priorities for any COVID-19 vaccination programme should be the prevention of...
NICE recommendation for GSK’s ovarian cancer treatment
National Institute for Health and Care Excellence (NICE) has recommended GSK’s ZEJULA®▼ (niraparib) on the NHS in England for women with advanced high-grade epithelial...